On Thursday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), gained 0.96% to $107.99.
Gilead Sciences declared that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The data comprised of in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older.
“With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “The R/F/TAF filing also represents the next step in our partnership with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Shares of BlackBerry Ltd (NASDAQ:BBRY), inclined 5.89% to $7.19, during its last trading session.
BlackBerry Limited, unveiled the BlackBerry Passport Silver Edition, a premium device built for business professionals who want a smartphone with the mobile tools they need to get things done - without sacrificing style or portability.
The BlackBerry Passport Silver Edition is in a class of its own, featuring a stunning silver finish with refined, curved corners, large square touch screen display and reinforced stainless steel frame for extra strength and durability. An essential business tool, the device delivers the same productivity enjoyed by other BlackBerry Passport products, in addition to an updated QWERTY touch-enabled keyboard, battery power that lasts more than a full day of mixed use, and BlackBerry10 OS 10.3.2.
“We strive to deliver products that combine cutting-edge technology with purposeful, globally recognized design, and the BlackBerry Passport Silver Edition is the latest manifestation of this vision,” said Scott Wenger, Global Head of Design at BlackBerry. “It brings together BlackBerry’s latest OS platform, improved productivity features, and a refined industrial design based on customer and user feedback to deliver an unmatched experience for professionals who value precision and focus.”
BlackBerry Limited provides wireless communications solutions worldwide. The company offers BlackBerry wireless solutions, which comprise the sale of BlackBerry handheld devices; and the provision of data communication, and compression and security infrastructure services enabling BlackBerry handheld wireless devices to send and receive wireless messages and data.
Finally, Parkway Properties Inc (NYSE:PKY), ended its last trade with 2.95% gain, and closed at $16.06.
Parkway Properties has declared a quarterly dividend of $0.1875 per share, payable on September 30, 2015 to shareholders of record of Common Stock on September 16, 2015. This dividend is the 116th successive quarterly distribution to Parkway’s shareholders of Common Stock and represents an annualized dividend rate of $0.75 per share.
Parkway Properties, Inc., a real estate investment trust (REIT), engages in the operation, acquisition, ownership, administration, and leasing of office properties. It operates and invests principally in office properties in the southeastern and southwestern United States and Chicago.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
